AVHHL
Price
$1.42
Change
-$0.01 (-0.70%)
Updated
May 16 closing price
Capitalization
512.89M
EXAS
Price
$56.48
Change
-$0.41 (-0.72%)
Updated
May 22, 04:59 PM (EDT)
Capitalization
12.78B
75 days until earnings call
Interact to see
Advertisement

AVHHL vs EXAS

Header iconAVHHL vs EXAS Comparison
Open Charts AVHHL vs EXASBanner chart's image
Avita Medical
Price$1.42
Change-$0.01 (-0.70%)
Volume$100
Capitalization512.89M
Exact Sciences
Price$56.48
Change-$0.41 (-0.72%)
Volume$415.16K
Capitalization12.78B
AVHHL vs EXAS Comparison Chart
Loading...
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVHHL vs. EXAS commentary
May 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVHHL is a Hold and EXAS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
May 22, 2025
Stock price -- (AVHHL: $1.42 vs. EXAS: $56.89)
Brand notoriety: AVHHL: Not notable vs. EXAS: Notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: AVHHL: 28% vs. EXAS: 122%
Market capitalization -- AVHHL: $512.89M vs. EXAS: $12.78B
AVHHL [@Medical Specialties] is valued at $512.89M. EXAS’s [@Medical Specialties] market capitalization is $12.78B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.5B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVHHL’s FA Score shows that 0 FA rating(s) are green whileEXAS’s FA Score has 0 green FA rating(s).

  • AVHHL’s FA Score: 0 green, 5 red.
  • EXAS’s FA Score: 0 green, 5 red.
According to our system of comparison, EXAS is a better buy in the long-term than AVHHL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXAS’s TA Score shows that 5 TA indicator(s) are bullish.

  • EXAS’s TA Score: 5 bullish, 4 bearish.

Price Growth

AVHHL (@Medical Specialties) experienced а -0.70% price change this week, while EXAS (@Medical Specialties) price change was +3.68% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.57%. For the same industry, the average monthly price growth was +7.15%, and the average quarterly price growth was -0.10%.

Reported Earning Dates

EXAS is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Medical Specialties (+0.57% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXAS($12.8B) has a higher market cap than AVHHL($513M). EXAS YTD gains are higher at: 1.246 vs. AVHHL (-44.531). EXAS has higher annual earnings (EBITDA): 29.3M vs. AVHHL (-25.8M). EXAS has more cash in the bank: 778M vs. AVHHL (73.5M). AVHHL has less debt than EXAS: AVHHL (1.87M) vs EXAS (2.56B). EXAS has higher revenues than AVHHL: EXAS (2.5B) vs AVHHL (37.4M).
AVHHLEXASAVHHL / EXAS
Capitalization513M12.8B4%
EBITDA-25.8M29.3M-88%
Gain YTD-44.5311.246-3,575%
P/E RatioN/AN/A-
Revenue37.4M2.5B1%
Total Cash73.5M778M9%
Total Debt1.87M2.56B0%
FUNDAMENTALS RATINGS
AVHHL vs EXAS: Fundamental Ratings
AVHHL
EXAS
OUTLOOK RATING
1..100
9026
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
44
Fair valued
PROFIT vs RISK RATING
1..100
79100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6439
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXAS's Valuation (44) in the Biotechnology industry is in the same range as AVHHL (69) in the null industry. This means that EXAS’s stock grew similarly to AVHHL’s over the last 12 months.

AVHHL's Profit vs Risk Rating (79) in the null industry is in the same range as EXAS (100) in the Biotechnology industry. This means that AVHHL’s stock grew similarly to EXAS’s over the last 12 months.

AVHHL's SMR Rating (100) in the null industry is in the same range as EXAS (100) in the Biotechnology industry. This means that AVHHL’s stock grew similarly to EXAS’s over the last 12 months.

EXAS's Price Growth Rating (39) in the Biotechnology industry is in the same range as AVHHL (64) in the null industry. This means that EXAS’s stock grew similarly to AVHHL’s over the last 12 months.

EXAS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as AVHHL (100) in the null industry. This means that EXAS’s stock grew similarly to AVHHL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXAS
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 3 days ago
70%
Declines
ODDS (%)
Bearish Trend 14 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
75%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GLTR134.911.60
+1.20%
abrdn Physical PrecMtlBsk Shrs ETF
UTWO48.27-0.03
-0.06%
US Treasury 2 Year Note ETF
XDQQ34.06-0.18
-0.52%
Innovator Gr 100 Acltd ETF™ Quarterly
VTI286.77-5.08
-1.74%
Vanguard Total Stock Market ETF
FAN16.95-0.35
-2.02%
First Trust Global Wind Energy ETF

AVHHL and

Correlation & Price change

A.I.dvisor tells us that AVHHL and FONR have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AVHHL and FONR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVHHL
1D Price
Change %
AVHHL100%
N/A
FONR - AVHHL
29%
Poorly correlated
-3.01%
AZTA - AVHHL
28%
Poorly correlated
-2.79%
EMITF - AVHHL
26%
Poorly correlated
N/A
MBGNF - AVHHL
24%
Poorly correlated
N/A
EXAS - AVHHL
22%
Poorly correlated
-1.59%
More

EXAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXAS has been loosely correlated with QGEN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAS jumps, then QGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXAS
1D Price
Change %
EXAS100%
-1.59%
QGEN - EXAS
55%
Loosely correlated
-0.89%
RGEN - EXAS
55%
Loosely correlated
-5.78%
CDNA - EXAS
33%
Poorly correlated
-3.89%
ILMN - EXAS
32%
Poorly correlated
-5.75%
FNA - EXAS
32%
Poorly correlated
N/A
More